This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Alzheimer's Disease
and you are
between 50 and 85
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

This study will examine whether the administration of galantamine is effective for improvement of attention and more effective for patients with serious disturbance of attention by administering galantamine to patients with Alzheimer's dementia and performing an attention test on baseline, week 4 and 12.

Provided treatments

  • Drug: Galantamine

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01054976. The sponsor of the trial is Janssen Korea, Ltd., Korea and it is looking for 99 volunteers for the current phase.
Official trial title:
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease